Another tyrosine kinase inhibitor neratinib, which is an intensive adjuvant drug for trastuzumab for early-stage HER-2-positive breast cancer patients, has insufficient evidence of cardiac adverse effect, but only causing diarrhea (91). Here, ERBB2 is linked to breast cancer.